NanoViricides (NNVC) AI Stock Analysis

• Market Cap: $24.16M
• Dividend Yield: N/A
• Average Volume (3M): 143.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.60
• Revenue Growth: N/A
• EPS Growth: 32.92%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 21,568,430
• 10 Day Avg. Volume: 199,739
• 30 Day Avg. Volume: 143,335
• PEG Ratio: 0.22
• Price to Book (P/B): 2.82
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.48
• Enterprise Value/Market Cap: 0.69
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -32.14
• Enterprise Value/Ebitda: -2.24
• 1Y Price Target: $6.00
• Price Target Upside: 430.97% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $1.00 ▼(-11.50% Downside)

The score is held down primarily by weak financial performance (pre-revenue, sizable recurring losses, and persistent cash burn) and bearish technical trends (price below key moving averages with negative momentum). A recent $6M financing modestly improves near-term liquidity, but valuation support is limited given negative earnings and no dividend.

Positive Factors

Innovative Drug Development

The advancement of NV-387 into Phase II trials highlights NanoViricides' innovative approach in addressing complex viral-related conditions, potentially expanding its market reach and enhancing its competitive position in the biotech industry.

Debt-Free Balance Sheet

Having no debt provides NanoViricides with financial flexibility and reduces risk, allowing the company to focus resources on R&D and strategic partnerships without the burden of interest payments.

Strategic Partnerships Potential

The company's focus on strategic partnerships can provide essential funding and resources, facilitating drug development and commercialization, which is crucial for long-term growth in the biotech sector.

Negative Factors

Lack of Revenue

The absence of revenue generation underscores the company's reliance on external funding, posing a risk to its financial sustainability and ability to invest in future growth without successful commercialization.

Consistent Operational Losses

Ongoing operational losses highlight financial instability, which could hinder NanoViricides' ability to sustain its R&D activities and delay potential market entry of its drug candidates.

Negative Cash Flows

Negative cash flows reflect the company's struggle to cover its operational expenses, necessitating continuous external financing, which may not be sustainable in the long term without achieving revenue growth.

NanoViricides Business Overview & Revenue Model

Company Description

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.

How the Company Makes Money

NanoViricides makes money primarily through the development and commercialization of its proprietary antiviral drug candidates. As the company is primarily in the research and development phase, its current revenue streams are limited to potential grants, research collaborations, and licensing agreements with larger pharmaceutical companies. These partnerships can provide funding and resources in exchange for rights to develop or market NanoViricides' technologies. Additionally, the company may earn revenue in the future through product sales once its drugs receive regulatory approval and are launched in the market. Until then, its financial health is heavily reliant on investment funding and strategic partnerships to support its ongoing research activities.

NanoViricides Financial Statement Overview

Summary

NanoViricides is facing significant financial challenges characterized by lack of revenue, consistent operational losses, and cash burn. While the capital structure shows no debt, the reliance on equity and financing for operations underscores the urgency for revenue generation to ensure long-term viability.

Income Statement

NanoViricides has not generated any revenue in the TTM (Trailing-Twelve-Months) or previous years, leading to consistent negative gross and net profit margins. The company operates at a loss with EBIT and EBITDA margins also being negative, indicating ongoing financial challenges.

Balance Sheet

The company maintains a favorable debt position with zero total debt in the latest TTM, resulting in a strong equity ratio. However, the declining stockholders' equity and total assets over time suggest potential concerns regarding asset management and equity preservation.

Cash Flow

NanoViricides has negative operating and free cash flows, indicating cash burn without revenue generation. The company relies on financing activities to support operations, which may not be sustainable long-term without revenue growth.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-519.88K	0.00	0.00	-747.53K	0.00	0.00
EBITDA	-7.44M	-8.72M	-7.49M	-7.84M	-7.38M	-8.04M
Net Income	-8.13M	-9.47M	-8.29M	-8.59M	-8.11M	-8.82M
Balance Sheet
Total Assets	8.36M	8.82M	12.82M	16.90M	23.49M	30.26M
Cash, Cash Equivalents and Short-Term Investments	1.13M	1.56M	4.80M	8.15M	14.07M	20.52M
Total Debt	0.00	0.00	0.00	0.00	94.79K	95.31K
Total Liabilities	1.18M	1.31M	1.36M	2.03M	412.84K	351.15K
Stockholders Equity	7.17M	7.52M	11.46M	14.87M	23.08M	29.91M
Cash Flow
Free Cash Flow	-7.57M	-8.54M	-6.47M	-5.82M	-6.22M	-8.45M
Operating Cash Flow	-7.48M	-8.48M	-6.32M	-5.67M	-5.89M	-8.21M
Investing Cash Flow	-94.52K	-56.96K	-156.56K	-151.71K	-324.35K	-238.76K
Financing Cash Flow	4.83M	5.30M	3.12M	-94.79K	-234.72K	15.26M

NanoViricides Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.13
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NNVC, the sentiment is Negative. The current price of 1.13 is below the 20-day moving average (MA) of 1.21, below the 50-day MA of 1.35, and below the 200-day MA of 1.41, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 41.73 is Neutral, neither overbought nor oversold. The STOCH value of 25.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NNVC.

NanoViricides Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SABS	50 Neutral	$175.19M	-1.21	-21.16%	―	-92.42%	62.37%
CASI	46 Neutral	$17.04M	-0.34	―	―	26.20%	-42.26%
ENLV	45 Neutral	$214.05M	-1.78	-57.64%	―	―	46.09%
MBRX	45 Neutral	$12.26M	-0.07	―	―	―	79.31%
NNVC	43 Neutral	$24.16M	-2.22	-94.03%	―	―	32.92%
AKTX	42 Neutral	$9.19M	―	-196.60%	―	―	―

NanoViricides Corporate Events

NanoViricides Holds 2025 Annual Stockholders Meeting

On November 22, 2025, NanoViricides, Inc. held its 2025 Annual Meeting of Stockholders, where approximately 61% of the company’s voting capital stock was represented. The shareholders approved the re-election of Anil Diwan as a Class I Director, an advisory vote on executive compensation, and the ratification of EisnerAmper, LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2026. These decisions reflect the company’s ongoing commitment to its leadership and financial oversight, potentially impacting its operational stability and investor confidence.

NanoViricides Secures $6 Million Through Securities Offering

On November 10, 2025, NanoViricides, Inc. entered into a securities purchase agreement with an institutional investor, resulting in a registered direct offering and a concurrent private placement that closed on November 12, 2025. The company raised approximately $6 million in gross proceeds, which it intends to use for working capital and general corporate purposes. The offering included the sale of common stock and warrants, with certain restrictions on future stock issuance and transactions. This financial maneuver is expected to bolster NanoViricides’ operational capabilities and support its ongoing drug development efforts, potentially strengthening its position in the antiviral therapy market.